Ambrisentan therapy in pulmonary hypertension: clinical use and tolerability in a referral centre.

Author: BillingsCatherine, CondliffeRobin, ElliotCharlie A, HamiltonNeil, HurdmanJudith, KielyDavid G, SabroeIan

Paper Details 
Original Abstract of the Article :
INTRODUCTION: Ambrisentan is an oral selective endothelin receptor antagonist licensed for use in pulmonary arterial hypertension (PAH). There are few data on clinical use and long-term tolerability in a wider range of patients with pulmonary hypertension (PH). METHODS: All patients treated with am...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1177/1753465814532304

データ提供:米国国立医学図書館(NLM)

Ambrisentan: Navigating the Desert of Pulmonary Hypertension

Pulmonary hypertension is a serious condition that can leave individuals struggling to breathe, feeling like they are trapped in a desert of breathlessness. This study explores the use of ambrisentan, a drug that targets the endothelin receptor system, in a large cohort of patients with pulmonary hypertension. The researchers examined the clinical use and long-term tolerability of ambrisentan in a real-world setting, providing valuable insights into its effectiveness and safety.

Ambrisentan: A Glimmer of Hope in the Desert of Pulmonary Hypertension

The study found that ambrisentan is a commonly used treatment for pulmonary hypertension, often employed as an initial therapy or as monotherapy. However, the researchers noted that discontinuation due to side effects, particularly edema, was more common than reported in previous studies. This is a reminder that navigating the desert of pulmonary hypertension requires careful monitoring and a collaborative approach with healthcare providers. Despite these challenges, the study also found that improvement in functional class was associated with superior survival, offering a ray of hope for individuals facing this challenging condition.

Navigating the Desert with Caution: Ambrisentan Treatment

The study's findings suggest that ambrisentan can be a valuable tool in managing pulmonary hypertension, but it is essential to approach treatment with caution. Consult with your doctor to determine if ambrisentan is the right treatment option for you and to discuss any potential risks and side effects. Remember, just as a desert traveler needs to be mindful of their resources and adapt to changing conditions, managing pulmonary hypertension requires a collaborative approach with your healthcare team, as well as a focus on lifestyle modifications and stress management techniques.

Dr. Camel's Conclusion

Ambrisentan is a frequently used treatment for pulmonary hypertension, but it's crucial to be aware of potential side effects and to work closely with your doctor for personalized management.

Date :
  1. Date Completed n.d.
  2. Date Revised 2019-11-20
Further Info :

Pubmed ID

24787237

DOI: Digital Object Identifier

10.1177/1753465814532304

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.